Group 1 - The core viewpoint of the news is that Kangmand Capital has conducted research on Lijuz Group, highlighting the promising clinical data of its IL-17A/F project (LZM012) for psoriasis, which shows superiority over Secukinumab and rapid onset of action [1] - Lijuz Group plans to develop LZM012 for ankylosing spondylitis and pyoderma gangrenosum, and aims to advance overseas licensing [1] - The company is establishing a small nucleic acid technology platform, starting with a gout project, to build a research and development system and production line [1] - In 2024, Lijuz Group intends to introduce six new drug projects to strengthen its leading position in chronic disease areas and expand its innovative drug pipeline [1] - The small nucleic acid project LZHN2408 and products with global revenue-sharing mechanisms are expected to facilitate overseas licensing [1] - The acquisition of Vietnam's IMP Company aims to establish a presence in the Southeast Asian market, integrate production capabilities, and promote overseas sales [1] - Lijuz Group is enhancing research and development efficiency through strategic research deployment, improved management structure, and strengthened project evaluation and adjustment management [1]